GlassScriptPhysician profile
Kashi S Bagri
NPI 1730166075
$3,625.78
in general payments reported to CMS, 2019-2025
24 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.13 · 2020: $47.02 · 2021: $522 · 2022: $767 · 2023: $1,439 · 2024: $384 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.98 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $661.55 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $590.65 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $477.89 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $296.26 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $236.91 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $223.26 | 2023-2025 | Invega Trinza, Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $206.52 | 2022-2023 | Jornay Pm |
| Alkermes, INC. | $97.33 | 2023-2025 | Aristada, Lybalvi |
| Indivior INC. | $91.43 | 2022-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $84.90 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $72.95 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $70.71 | 2023 | Quviviq |
| Neos Therapeutics, LP | $70.54 | 2022-2023 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $69.67 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $65.89 | 2021-2023 | Pifeltro, Delstrigo, Isentress |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $60.27 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $56.84 | 2023 | Fanapt, Hetlioz |
| Lundbeck LLC | $49.42 | 2022 | |
| Supernus Pharmaceuticals, INC. | $38.35 | 2022-2024 | Qelbree |
| Theratechnologies INC. | $24.24 | 2022 | |
| Gilead Sciences, INC. | $22.70 | 2023 | Epclusa |
| Janssen Biotech, INC. | $22.23 | 2022 | |
| Napo Pharmaceuticals INC | $20.27 | 2021 | |
| Allergan, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashi Bagri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.